November 15, 2015.
One committee member who voted no said that randomized data on BPC-157 suggested it may perform no better than placebo, and that known potential risks, including liver damage, would not be reliably detected through patient self-reporting
You can, but we don't recommend it
In some cases, especially at the beginning of treatment for a severe deficiency, injections might be given more frequently (e.g., daily or every other day) for a short period before transitioning to a maintenance schedule
Originally developed in the 1990s as a potential anti-obesity drug, AOD-9604 was designed to: Stimulate lipolysis (breakdown of fat) Inhibit lipogenesis (formation of new fat) Avoid the risks associated with full-length HGH, such as IGF-1 elevation, acromegaly, or glucose intolerance Today, AOD-9604 is available through compounding pharmacies and research peptide suppliers, often marketed for weight loss, metabolic health, and body composition improvement